Downstream Process Intensification with Novel Chromatography Resins for Enhanced Monoclonal Antibody Purification
In this presentation, we will demonstrate an integrated mAbs downstream purification process to enable significant throughput improvement while removing of critical impurities. The process approach includes (1) pre-absorption filtration technology and (2) buffer additives. Through use of pre-absorption filtration technology, in combination with PROchievA protein A affinity resin, that possess high dynamic binding capacities of greater than 60 g/L, we have obtained antibodies with increased purity, while reducing overall process time. Furthermore, by using select additives during process chromatography, we demonstrate this process can be 'fine tuned' to enhance target antibody selectivity by removing host cell protein impurities and aggregates. When used in conjunction, these technologies represent a highly efficient process to obtain monoclonal antibodies for use as therapeutics.
Presented as part of the Avantor webinar programme in June 2020.
Presented by:
 |
|
Jonathan Fura is Manager, Research & Development at Avantor. In his current role, Jonathan focuses on developing technologies that are utilised to advance the development and manufacturing of antibody-based biopharmaceuticals and diagnostics. Jonathan holds a Ph.D. in chemistry with a focus on developing immunomodulation therapeutic strategies. |
| |
 |
|
Jungmin Oh is Manager, New Product Development at Avantor. In her current role, Jungmin leads product and process development projects with multiple biopharmaceutical industry partners, including customised product development for cell and gene therapy customers. She holds a MS and Ph.D. in chemical engineering, specialising in the optimisation of a continuous chromatography system. |
| |
 |
|
Joshua Sumoski is an Innovation Scientist at Avantor. In his current role, Joshua focuses on downstream purification process development and chromatography product support. He has over 15 years of experience within the biotech/pharma industry in both process development and manufacturing. |
|
